Biosimilars: How Many Votes Is A Chairmanship Worth?
This article was originally published in The Pink Sheet Daily
Executive Summary
Eshoo introduces her biosimilars bill with 43 co-sponsors, but Waxman controls the agenda.
You may also be interested in...
FOB debate awaits Kennedy/Enzi bill
Rep. Henry Waxman's follow-on biologics bill arrives in the Senate March 26, courtesy of Chuck Schumer, D-N.Y., as S. 726, with three Republican and four Democrat co-sponsors, including Schumer. Meanwhile, Waxman is now joined by two Democrats and four Republicans in backing H.R. 1427. This compares to 54 co-sponsors signing on to Rep. Anna Eshoo's H.R. 1548 (1"The Pink Sheet" DAILY, March 18, 2009). Biosimilars legislation reported by the Senate Health, Education, Labor and Pensions Committee in 2008 will be re-introduced by Sens. Ted Kennedy, D-Mass., and Michael Enzi, R-Wyo., as soon as an agreement is reached on language to clarify how biologics can be modified and still qualify as innovative and gain 12 years of data exclusivity
FOB debate awaits Kennedy/Enzi bill
Rep. Henry Waxman's follow-on biologics bill arrives in the Senate March 26, courtesy of Chuck Schumer, D-N.Y., as S. 726, with three Republican and four Democrat co-sponsors, including Schumer. Meanwhile, Waxman is now joined by two Democrats and four Republicans in backing H.R. 1427. This compares to 54 co-sponsors signing on to Rep. Anna Eshoo's H.R. 1548 (1"The Pink Sheet" DAILY, March 18, 2009). Biosimilars legislation reported by the Senate Health, Education, Labor and Pensions Committee in 2008 will be re-introduced by Sens. Ted Kennedy, D-Mass., and Michael Enzi, R-Wyo., as soon as an agreement is reached on language to clarify how biologics can be modified and still qualify as innovative and gain 12 years of data exclusivity
Biosimilar Interchangeability Does Not Equate To Substitution Under House Legislation
Bills from Rep. Waxman and Rep. Eshoo differ in their approaches, but both leave a lot of work to the states.